Literature DB >> 1692082

Synthesis of granulocyte colony-stimulating factor and its requirement for terminal divisions in chronic myelogenous leukemia.

H Klein1, R Becher, M Lübbert, W Oster, E Schleiermacher, M A Brach, L Souza, A Lindemann, R H Mertelsmann, F Herrmann.   

Abstract

In this paper we demonstrate that maturing neoplastic cells from patients with chronic myelogenous leukemia (CML) constitutively produce G-CSF and are also receptive for this molecule. G-CSF functions as an autocrine growth factor in stable phase CML, and thus is responsible for divisions of maturing leukemic cells leading to an expansion of the compartment of mature cells. This observation is well in line with in vivo features of CML in stable phase, i.e., the hyperplasia of the mature granulocyte compartment. In acute blastic phase of CML expression of the G-CSF gene seems to be less common and not related to autonomous blast growth.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692082      PMCID: PMC2187899          DOI: 10.1084/jem.171.5.1785

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  12 in total

1.  Chromosome studies on normal and leukemic human leukocytes.

Authors:  P C NOWELL; D A HUNGERFORD
Journal:  J Natl Cancer Inst       Date:  1960-07       Impact factor: 13.506

2.  In vitro regulation of human hematopoiesis by natural killer cells: analysis at a clonal level.

Authors:  F Herrmann; R E Schmidt; J Ritz; J D Griffin
Journal:  Blood       Date:  1987-01       Impact factor: 22.113

3.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

Review 5.  Biology of chronic myelogenous leukemia: is discordant maturation the primary defect?

Authors:  A Strife; B Clarkson
Journal:  Semin Hematol       Date:  1988-01       Impact factor: 3.851

6.  Growth characteristics of leukemic and normal hematopoietic cells in Ph' + chronic myelogenous leukemia and effects of intensive treatment.

Authors:  T Goto; M Nishikori; Z Arlin; T Gee; S Kempin; J Burchenal; A Strife; D Wisniewski; C Lambek; C Little; S Jhanwar; R Chaganti; B Clarkson
Journal:  Blood       Date:  1982-04       Impact factor: 22.113

7.  Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia.

Authors:  D C Young; K Wagner; J D Griffin
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

8.  Structure and expression of genes of GM-CSF and G-CSF in blast cells from patients with acute myeloblastic leukemia.

Authors:  G Y Cheng; C A Kelleher; J Miyauchi; C Wang; G Wong; S C Clark; E A McCulloch; M D Minden
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

9.  Localization of the G-CSF gene on chromosome 17 proximal to the breakpoint in the t(15;17) in acute promyelocytic leukemia.

Authors:  R N Simmers; L M Webber; M F Shannon; O M Garson; G Wong; M A Vadas; G R Sutherland
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

10.  The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells.

Authors:  A Muraguchi; T Hirano; B Tang; T Matsuda; Y Horii; K Nakajima; T Kishimoto
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  5 in total

1.  Regulation of granulocytosis in inflammatory disease and in leukemia.

Authors:  P Reizenstein; L Stenke
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

Review 2.  Biotherapy of chronic myelogenous leukemia.

Authors:  W E Aulitzky; C Peschel; F Schneller; C Huber
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

3.  Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-alpha-treated chronic myelogenous leukaemia patients.

Authors:  G Pawelec; G Ehninger; H Schmidt; C Müller; H J Bühring; M Reutter; F W Busch
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 4.  Interleukin-6 in clinical medicine.

Authors:  J Bauer; F Herrmann
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

5.  The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.

Authors:  Karin Gustafsson; Maria Jamalpour; Camilla Trinh; Michael G Kharas; Michael Welsh
Journal:  J Hematol Oncol       Date:  2014-06-21       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.